Stocks of Vir Biotechnology Inc. (NASDAQ:VIR) traded higher last session on Wall Street, up 1.30% to $24.85.
According to the data, Vir Biotechnology Inc. (NASDAQ:VIR) has 9 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $100.00 and a low of $27.00, we find $39.00. Given the previous closing price of $24.53, this indicates a potential upside of 58.99 percent. VIR stock price is now -2.00% away from the 50-day moving average and 0.66% away from the 200-day moving average. The market capitalization of the company currently stands at $3.32B.
A total of 1 analysts have issued a hold rating and 7 have given it a buy rating. Brokers who have rated the stock have averaged $47.75 as their price target over the next twelve months.
With the price target reduced from $35 to $34, JP Morgan Upgraded its rating from Neutral to Overweight for Vir Biotechnology Inc. (NASDAQ: VIR).
In other news, SATO VICKI L, Director sold 18,000 shares of the company’s stock on Jun 30. The stock was sold for $443,916 at an average price of $24.66. Upon completion of the transaction, the Director now directly owns 1,315,351 shares in the company, valued at $32.69 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 29, 10% Owner SVF Endurance (Cayman) Ltd sold 89,942 shares of the business’s stock. A total of $2,264,731 was realized by selling the stock at an average price of $25.18. This leaves the insider owning 16,684,741 shares of the company worth $414.62 million. Insiders disposed of 10,541,133 shares of company stock worth roughly $261.95 million over the past 1 year. A total of 1.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VIR stock. A new stake in Vir Biotechnology Inc. shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $41,438,000. SOFINNOVA INVESTMENTS, INC. invested $16,189,000 in shares of VIR during the first quarter. In the first quarter, BRAIDWELL LP acquired a new stake in Vir Biotechnology Inc. valued at approximately $14,871,000. BALYASNY ASSET MANAGEMENT L.P. acquired a new stake in VIR for approximately $9,921,000. JUPITER ASSET MANAGEMENT LTD purchased a new stake in VIR valued at around $9,692,000 in the second quarter. In total, there are 338 active investors with 76.10% ownership of the company’s stock.
Monday’s opening bell rang with an opening price of $24.41 for Vir Biotechnology Inc. (NASDAQ: VIR). During the past 12 months, Vir Biotechnology Inc. has had a low of $18.05 and a high of $31.78. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.90, and a quick ratio of 4.90. The fifty day moving average price for VIR is $25.36 and a two-hundred day moving average price translates $24.69 for the stock.
The latest earnings results from Vir Biotechnology Inc. (NASDAQ: VIR) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$1.06, missing analysts’ expectations of -$0.87 by -0.19. This compares to $3.85 EPS in the same period last year. The net profit margin was -32.20% and return on equity was -7.10% for VIR. The company reported revenue of $62.96 million for the quarter, compared to $1.23 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -94.89 percent. For the current quarter, analysts expect VIR to generate $23.06M in revenue.
